(Bloomberg) — Moderna Inc.’s experimental vaccine for Covid-19 could generate sales of more than $5 billion a year, Jefferies analyst Michael Yee said, initiating the stock at a buy.The shares jumped as much as 5.6% in Monday trading after the bullish review. A more than 230% surge for the stock since the start of the year has split Wall Street as to “what will happen or if the vaccine will even work,” and investors are “hugely divided on valuation,” Yee wrote in his note to clients.“We believe the Street will be surprised to the upside if the Covid-19 vaccine works, …read more
Source:: Yahoo Finance
